Nasdaq

New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer

AUSTIN, Texas, July 28, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology ...
Yahoo Finance

Natera’s Signatera test to be used in Phase III bladder cancer trial

US-based clinical genetic testing company Natera said that its Signatera test will be utilised in the newly activated ARCHER trial, a Phase III study sponsored by NRG Oncology. The trial focuses on ...
Nasdaq

FDA Grants Breakthrough Device Designation to Natera's Signatera Test

SAN CARLOS, Calif., May 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its ...
Business Insider

Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera™ MRD Test in Colorectal Cancer

SAN CARLOS, Calif., Aug. 22, 2019/PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the Palmetto MolDX program has proposed a local coverage ...
CURE

This Test Helped Identify Treatment in Colorectal Cancer Surgery

Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival ...
Business Wire

Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & ...
Business Wire

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...
Morningstar

Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), ...
Business Insider

Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera™ MRD Testing

SAN CARLOS, Calif., June 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that enrollment has begun in the CIRCULATE-Japan ...

JP Morgan lifts Natera, Inc. (NTRA) target on Signatera momentum

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Natera, Inc. stands fifth on our list among the most promising stocks. TheFly reported on December 15 ...
Yahoo Finance

Natera’s Signatera test to be used in Phase III bladder cancer trial

Natera's Signatera test included in NRG-sponsored bladder cancer study. Credit: Michael Vi / Shutterstock.com. · Medical Device Network · Michael Vi / Shutterstock.com. US-based clinical genetic ...